Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals

Implications for medication dosing for transgender patients: A review of the literature and recommendations for pharmacists

(2020) Andrew J Webb et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Drug-drug interactions among Thai HIV-positive transgender women undergoing feminizing hormone therapy and antiretroviral therapy: the iFACT study

(2020) Akarin Hiransuthikul et al.   CLINICAL INFECTIOUS DISEASES

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV

(2020) H‐J Stellbrink et al.   HIV MEDICINE

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy

(2020) Lauren R Cirrincione et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

(2020) Robert Ross et al.   Nature Reviews Endocrinology

Antiretroviral therapy in older people with HIV

(2020) Aaron Richterman et al.   Current Opinion in HIV and AIDS

Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy

(2020) Jenna L. Yager et al.   Expert Opinion on Drug Metabolism & Toxicology

Hepatitis C seroprevalence and engagement in related care and treatment among trans women

(2019) Erin C. Wilson et al.   JOURNAL OF VIRAL HEPATITIS

Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy

(2019) Nienke M. Nota et al.   CIRCULATION

Cardiac arrhythmia considerations of hormone cancer therapies

(2019) Mary Barber et al.   CARDIOVASCULAR RESEARCH

Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre-exposure prophylaxis (PrEP)

(2019) Mackenzie L Cottrell et al.   CLINICAL INFECTIOUS DISEASES

Gender‐affirming hormonal treatment decreases bone turnover in trans women and older trans men

(2019) Mariska C Vlot et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Medroxyprogesterone acetate (MPA) concentrations among HIV-infected depot-medroxyprogesterone acetate (DMPA) users receiving antiretroviral therapy (ART) in Lilongwe, Malawi

(2019) Yasaman Zia et al.   CONTRACEPTION

Bone Densitometry in Transgender and Gender Nonconforming (TGNC) Individuals: The 2019 ISCD Official Positions

(2019) Harold N. Rosen et al.   JOURNAL OF CLINICAL DENSITOMETRY

Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study

(2019) Akarin Hiransuthikul et al.   Journal of the International AIDS Society

Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency

(2019) R Mngqibisa et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study

(2019) Kimberly K Scarsi et al.   Lancet HIV

Testosterone and androstenedione are endogenous substrates of P-glycoprotein

(2019) Kentaro Yano et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Fracture Risk in Trans Women and Trans Men Using Long‐Term Gender‐Affirming Hormonal Treatment: A Nationwide Cohort Study

(2019) Chantal M Wiepjes et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

(2019) Eugenie Shieh et al.   Journal of the International AIDS Society

Changes in Body Mass Index and Atherosclerotic Disease Risk Score after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide

(2019) Jason J Schafer et al.   Open Forum Infectious Diseases

Analysis of drug–drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database

(2018) Nimish Patel et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons

(2018) Darios Getahun et al.   ANNALS OF INTERNAL MEDICINE

Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection

(2018) Andreina A. Ottman et al.   ANNALS OF PHARMACOTHERAPY

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection

(2018) Kimberly L. Garrison et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

(2018) Rebecca Begley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Levels of depression in transgender people and its predictors: Results of a large matched control study with transgender people accessing clinical services

(2018) Gemma L. Witcomb et al.   JOURNAL OF AFFECTIVE DISORDERS

PharmGKB summary

(2018) Maria Alvarellos et al.   Pharmacogenetics and Genomics

Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications

(2018) Pierre Giguère et al.   CANADIAN JOURNAL OF CARDIOLOGY

The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality

(2018) Shejil Kumar et al.   Frontiers in Endocrinology

Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis

(2017) Spyridoula Maraka et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis

(2017) Naykky Singh-Ospina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline

(2017) Wylie C Hembree et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

(2017) Katie R Mollan et al.   JOURNAL OF INFECTIOUS DISEASES

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

(2017) Hannan M. Braun et al.   LGBT Health

HIV Diagnoses and Care Among Transgender Persons and Comparison With Men Who Have Sex With Men: New York City, 2006–2011

(2016) Ellen Weiss Wiewel et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis

(2016) M. Klaver et al.   ANDROLOGIA

Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients

(2016) Bernadette Jakeman et al.   ANNALS OF PHARMACOTHERAPY

Abacavir and cardiovascular disease: A critical look at the data

(2016) Josep M. Llibre et al.   ANTIVIRAL RESEARCH

Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV

(2016) Kimberly K. Scarsi et al.   DRUG SAFETY

Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms

(2016) Denise Kreutzwiser et al.   Expert Opinion on Drug Metabolism & Toxicology

Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation inCYP2B6*6*6Allele Carriers

(2016) AHMED M. ABDELHADY et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data

(2016) Alessandra D. Fisher et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol

(2016) Justin D. Arnold et al.   Journal of Sexual Medicine

Transgender people: health at the margins of society

(2016) Sam Winter et al.   LANCET

17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle

(2016) Andrea Magri et al.   LIVER INTERNATIONAL

Pharmacotherapy Considerations in the Management of Transgender Patients: An Alternative Viewpoint

(2016) Caitlin Leach et al.   PHARMACOTHERAPY

Depot Medroxyprogesterone Acetate in Combination with a Twice-Daily Lopinavir-Ritonavir-Based Regimen in HIV-Infected Women Showed Effective Contraception and a Lack of Clinically Significant Interactions, with Good Safety and Tolerability: Results of the ACTG 5283 Study

(2015) Amneris E. Luque et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

(2015) AC Achhra et al.   HIV MEDICINE

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

(2015)   LANCET INFECTIOUS DISEASES

Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review

(2015) Bryan M. Bishop   PHARMACOTHERAPY

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

(2014) Calvin Cohen et al.   AIDS

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps

(2014) Donald R. Mattison et al.   CRITICAL REVIEWS IN TOXICOLOGY

HIV treatment cascade among transgender women in a San Francisco respondent driven sampling study

(2014) Glenn-Milo Santos et al.   SEXUALLY TRANSMITTED INFECTIONS

Hormonal Therapy Is Associated With Better Self-esteem, Mood, and Quality of Life in Transsexuals

(2013) Audrey Gorin-Lazard et al.   JOURNAL OF NERVOUS AND MENTAL DISEASE

Effects of Different Steps in Gender Reassignment Therapy on Psychopathology: A Prospective Study of Persons with a Gender Identity Disorder

(2013) Gunter Heylens et al.   Journal of Sexual Medicine

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

(2012) Calvin J. Cohen et al.   AIDS

Complicated Atazanavir-Associated Cholelithiasis: A Report of 14 Cases

(2012) S. Rakotondravelo et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

(2012) Calvin J. Cohen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Worldwide burden of HIV in transgender women: a systematic review and meta-analysis

(2012) Stefan D Baral et al.   LANCET INFECTIOUS DISEASES

The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women

(2011) Heather Sevinsky et al.   ANTIVIRAL THERAPY

Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco

(2011) Albert Y. Liu et al.   PLoS One

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

(2010) Marisa Tungsiripat et al.   AIDS

Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs

(2010) Thomas N. Kakuda et al.   CLINICAL PHARMACOKINETICS

Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188

(2010) Mary A Vogler et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

Up-Regulation of UDP-Glucuronosyltransferase (UGT) 1A4 by 17 -Estradiol: A Potential Mechanism of Increased Lamotrigine Elimination in Pregnancy

(2009) H. Chen et al.   DRUG METABOLISM AND DISPOSITION

Induction of Multiple Drug Transporters by Efavirenz

(2009) Johanna Weiss et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men

(2008) Anna Lundahl et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

(2007) Kavita Nanda et al.   FERTILITY AND STERILITY